Free Trial

Turnstone Biologics (TSBX) Competitors

Turnstone Biologics logo
$0.36 0.00 (-0.52%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$0.36 +0.00 (+0.50%)
As of 04:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TSBX vs. KZR, RNTX, BDRX, KALA, ESLA, EGRX, EYEN, SXTC, MRNS, and ALLK

Should you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include Kezar Life Sciences (KZR), Rein Therapeutics (RNTX), Biodexa Pharmaceuticals (BDRX), KALA BIO (KALA), Estrella Immunopharma (ESLA), Eagle Pharmaceuticals (EGRX), Eyenovia (EYEN), China SXT Pharmaceuticals (SXTC), Marinus Pharmaceuticals (MRNS), and Allakos (ALLK). These companies are all part of the "pharmaceutical products" industry.

Turnstone Biologics vs. Its Competitors

Kezar Life Sciences (NASDAQ:KZR) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Kezar Life Sciences' return on equity of -61.15% beat Turnstone Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kezar Life SciencesN/A -61.15% -50.27%
Turnstone Biologics N/A -162.79%-124.10%

In the previous week, Kezar Life Sciences had 2 more articles in the media than Turnstone Biologics. MarketBeat recorded 2 mentions for Kezar Life Sciences and 0 mentions for Turnstone Biologics. Turnstone Biologics' average media sentiment score of 0.00 beat Kezar Life Sciences' score of -1.00 indicating that Turnstone Biologics is being referred to more favorably in the news media.

Company Overall Sentiment
Kezar Life Sciences Negative
Turnstone Biologics Neutral

Turnstone Biologics has higher revenue and earnings than Kezar Life Sciences. Kezar Life Sciences is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kezar Life Sciences$7M4.73-$83.74M-$10.82-0.42
Turnstone Biologics$19.31M0.44-$70.84M-$2.73-0.13

67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 52.5% of Turnstone Biologics shares are held by institutional investors. 9.3% of Kezar Life Sciences shares are held by company insiders. Comparatively, 32.1% of Turnstone Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kezar Life Sciences presently has a consensus target price of $39.50, indicating a potential upside of 771.96%. Turnstone Biologics has a consensus target price of $0.45, indicating a potential upside of 23.90%. Given Kezar Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kezar Life Sciences is more favorable than Turnstone Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kezar Life Sciences
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Turnstone Biologics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Kezar Life Sciences has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Turnstone Biologics has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.

Summary

Kezar Life Sciences beats Turnstone Biologics on 8 of the 15 factors compared between the two stocks.

Get Turnstone Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TSBX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TSBX vs. The Competition

MetricTurnstone BiologicsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.45M$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.04%
P/E Ratio-0.1320.8026.9620.11
Price / Sales0.44286.27430.20119.79
Price / CashN/A41.1936.8257.86
Price / Book0.277.487.985.56
Net Income-$70.84M-$55.04M$3.16B$248.40M
7 Day Performance0.86%2.44%2.39%4.67%
1 Month Performance-0.74%1.90%2.18%6.64%
1 Year Performance-84.14%4.35%33.82%21.31%

Turnstone Biologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TSBX
Turnstone Biologics
1.5663 of 5 stars
$0.36
-0.5%
$0.45
+23.9%
-83.9%$8.45M$19.31M-0.1382
KZR
Kezar Life Sciences
4.0147 of 5 stars
$4.40
-3.9%
$39.50
+797.7%
-17.2%$32.15MN/A-0.4160Negative News
RNTX
Rein Therapeutics
N/A$1.45
+3.6%
N/AN/A$32.12MN/A-0.519
BDRX
Biodexa Pharmaceuticals
N/A$0.87
+0.6%
N/AN/A$31.79M$470K0.0020Upcoming Earnings
KALA
KALA BIO
3.4674 of 5 stars
$4.84
+1.7%
$13.50
+178.9%
-24.2%$31.22M$3.89M-0.5930News Coverage
High Trading Volume
ESLA
Estrella Immunopharma
2.1999 of 5 stars
$0.86
-10.3%
$16.00
+1,758.7%
-29.7%$31.14MN/A-3.31N/APositive News
EGRX
Eagle Pharmaceuticals
N/A$2.36
-18.6%
N/A-45.9%$30.65M$257.55M0.00100
EYEN
Eyenovia
0.996 of 5 stars
$10.56
+1.7%
$2.00
-81.1%
-77.3%$30.41M$60K-0.1840
SXTC
China SXT Pharmaceuticals
0.1482 of 5 stars
$1.92
+11.0%
N/A-79.1%$30.39M$1.82M0.0090News Coverage
MRNS
Marinus Pharmaceuticals
2.3196 of 5 stars
$0.55
-0.2%
$3.92
+613.3%
-54.2%$30.32M$30.99M-0.22110
ALLK
Allakos
3.0215 of 5 stars
$0.33
flat
$2.00
+507.7%
N/A$29.74MN/A-0.16190

Related Companies and Tools


This page (NASDAQ:TSBX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners